The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Vimentin is a novel AKT1 target mediating motility and invasion
Open accessAbstract
The PI3K/AKT signaling pathway is aberrant in a wide variety of cancers. Downstream effectors of AKT are involved in survival, growth and metabolic-related pathways. In contrast, contradictory data relating to AKT effects on cell motility and invasion, crucial prometastatic processes, have been reported pointing to a potential cell type and isoform type-specific AKT-driven function. By implication, study of AKT signaling should optimally be conducted in an appropriate intracellular environment. Prognosis in soft-tissue sarcoma (STS), the aggressive malignancies of mesenchymal origin, is poor, reflecting our modest ability to control metastasis, an effort hampered by lack of insight into molecular mechanisms driving STS progression and dissemination. We examined the impact of the cancer progression-relevant AKT pathway on the mesenchymal tumor cell internal milieu. We demonstrate that AKT1 activation induces STS cell motility and invasiveness at least partially through a novel interaction with the intermediate filament vimentin (Vim). The binding of AKT (tail region) to Vim (head region) results in Vim Ser39 phosphorylation enhancing the ability of Vim to induce motility and invasion while protecting Vim from caspase-induced proteolysis. Moreover, vimentin phosphorylation was shown to enhance tumor and metastasis growth in vivo. Insights into this mesenchymal-related molecular mechanism may facilitate the development of critically lacking therapeutic options for these devastating malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prognostic Significance of Activated AKT Expression in Soft-Tissue Sarcoma
Tomita, Y., Morooka, T., Hoshida, Y., Zhang, B., Qiu, Y., Nakamichi, I., Hamada, K.-I., Ueda, T., Naka, N., Kudawara, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1732 · Cited by 59
Cited by
Vimentin in cancer and its potential as a molecular target for cancer therapy
Satelli, A., & Li, S. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0735-1 · Cited by 1,557
Post-translational modifications of intermediate filament proteins: mechanisms and functions
Snider, N. T., & Omary, M. B. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3753 · Cited by 524
Kaufhold, S., & Bonavida, B. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/preaccept-1929235422128885 · Cited by 469
Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis
Usman, S., Waseem, N. H., Nguyen, T. K. N., Mohsin, S., Jamal, A., Teh, M.-T., & Waseem, A. (2021) · Cancers · doi:10.3390/cancers13194985 · Cited by 430
Self-citationThe Role of Vimentin Intermediate Filaments in the Progression of Lung Cancer
Kidd, M. E., Shumaker, D. K., & Ridge, K. M. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0314tr · Cited by 330
Xu, J., Liu, D., Niu, H., Zhu, G., Xu, Y., Ye, D., Li, J., & Zhang, Q. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0487-8 · Cited by 283
Intermediate Filaments Play a Pivotal Role in Regulating Cell Architecture and Function
Lowery, J., Kuczmarski, E. R., Herrmann, H., & Goldman, R. D. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.640359 · Cited by 281
Vimentin organization modulates the formation of lamellipodia
Helfand, B. T., Mendez, M. G., Murthy, S. N. P., Shumaker, D. K., Grin, B., Mahammad, S., Aebi, U., Wedig, T., Wu, Y. I., Hahn, K. M., et al. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-08-0699 · Cited by 268
PKB/Akt-Dependent Regulation of Cell Motility
Xue, G., & Hemmings, B. A. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs648 · Cited by 265
Vimentin Diversity in Health and Disease
Danielsson, F., Peterson, M. K., Caldeira Araújo, H., Lautenschläger, F., & Gad, A. K. B. (2018) · Cells · doi:10.3390/cells7100147 · Cited by 265
The Cytoskeleton as Regulator of Cell Signaling Pathways
Moujaber, O., & Stochaj, U. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.11.003 · Cited by 158
Vimentin as antigenic target in autoimmunity: A comprehensive review
Musaelyan, A., Lapin, S., Nazarov, V., Tkachenko, O., Gilburd, B., Mazing, A., Mikhailova, L., & Shoenfeld, Y. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.04.004 · Cited by 111
Piotrowski-Daspit, A. S., Tien, J., & Nelson, C. M. (2016) · Integrative Biology · doi:10.1039/c5ib00282f · Cited by 101
The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma
Sims, D., Maranyane, H. M., Damerell, V., Govender, D., Isaacs, A. W., Peres, J., & Prince, S. (2020) · Cancers · doi:10.3390/cancers12020501 · Cited by 13
Metadata
- Authors
- Zhu, Q.-S., Rosenblatt, K., Huang, K.-L., Lahat, G., Brobey, R., Bolshakov, S., Nguyen, T., Ding, Z., Belousov, R., Bill, K., Luo, X., Lazar, A., Dicker, A., Mills, G. B., Hung, M.-C., & Lev, D.
- Venue
- Oncogene
- Published
- 2010-09-20
- Volume
- 30
- Issue
- 4
- Pages
- 457-470
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2014331589
- Cited by
- 246
- References
- 1
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.